JP2020514284A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514284A5
JP2020514284A5 JP2019535381A JP2019535381A JP2020514284A5 JP 2020514284 A5 JP2020514284 A5 JP 2020514284A5 JP 2019535381 A JP2019535381 A JP 2019535381A JP 2019535381 A JP2019535381 A JP 2019535381A JP 2020514284 A5 JP2020514284 A5 JP 2020514284A5
Authority
JP
Japan
Prior art keywords
amino
chloroisoquinoline
alkyl
picoline amide
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019535381A
Other languages
English (en)
Japanese (ja)
Other versions
JP7144863B2 (ja
JP2020514284A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/058438 external-priority patent/WO2018122746A1/en
Publication of JP2020514284A publication Critical patent/JP2020514284A/ja
Publication of JP2020514284A5 publication Critical patent/JP2020514284A5/ja
Application granted granted Critical
Publication of JP7144863B2 publication Critical patent/JP7144863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019535381A 2016-12-28 2017-12-27 イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用 Active JP7144863B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382660 2016-12-28
EP16382660.5 2016-12-28
PCT/IB2017/058438 WO2018122746A1 (en) 2016-12-28 2017-12-27 Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase

Publications (3)

Publication Number Publication Date
JP2020514284A JP2020514284A (ja) 2020-05-21
JP2020514284A5 true JP2020514284A5 (cg-RX-API-DMAC10.html) 2021-02-12
JP7144863B2 JP7144863B2 (ja) 2022-09-30

Family

ID=57777485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535381A Active JP7144863B2 (ja) 2016-12-28 2017-12-27 イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用

Country Status (13)

Country Link
US (1) US11440898B2 (cg-RX-API-DMAC10.html)
EP (1) EP3562821B9 (cg-RX-API-DMAC10.html)
JP (1) JP7144863B2 (cg-RX-API-DMAC10.html)
CN (1) CN110494432B (cg-RX-API-DMAC10.html)
AU (1) AU2017388300B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019013593A2 (cg-RX-API-DMAC10.html)
CA (1) CA3047700A1 (cg-RX-API-DMAC10.html)
DK (1) DK3562821T3 (cg-RX-API-DMAC10.html)
ES (1) ES2862374T3 (cg-RX-API-DMAC10.html)
IL (1) IL267553B (cg-RX-API-DMAC10.html)
PL (1) PL3562821T3 (cg-RX-API-DMAC10.html)
PT (1) PT3562821T (cg-RX-API-DMAC10.html)
WO (1) WO2018122746A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023042177A1 (en) 2021-09-20 2023-03-23 Gt Gain Therapeutics Sa Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide
CN122122139A (zh) * 2023-11-02 2026-05-29 Gt增益治疗股份有限公司 取代的吲哚基化合物、其组合物及其治疗用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
DE19740785A1 (de) 1997-02-21 1998-08-27 Bayer Ag Arylsulfonamide und Analoga
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
WO2001058899A1 (en) 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
EP1433776B1 (en) 2001-09-07 2011-01-19 Seikagaku Corporation Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient
JP2006519258A (ja) 2003-02-28 2006-08-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ii受容体拮抗薬
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2005070929A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Akt活性のある阻害剤
CA2555914A1 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
WO2006058201A2 (en) * 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
AU2006204750C1 (en) 2005-01-14 2012-11-01 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
AT502145B1 (de) 2005-03-24 2012-01-15 Univ Graz Tech Glycosidase-hemmendes iminoalditol
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
JP5249770B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
JP2010500330A (ja) 2006-08-10 2010-01-07 フエルレル インターナショナル,ソシエダッド アノニマ Gabaa受容体に対して親和性を有する1h−キノリン−4−オン化合物、方法、使用及び組成物
EP1903034A1 (en) 2006-09-19 2008-03-26 Technische Universität Graz Iminosugar glycoconjugates
WO2009042294A2 (en) 2007-08-10 2009-04-02 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
WO2009049422A1 (en) 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
CN102743385B (zh) * 2007-11-16 2014-09-17 沃泰克斯药物股份有限公司 Atp结合盒转运蛋白的异喹啉调节剂
ES2337435B8 (es) 2008-10-22 2011-07-19 Consejo Superior De Investigaciones Cientificas (Csic) (25%) Compuestos potenciadores de la actividad de glicosidasas mutantes.
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
WO2011049737A1 (en) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
WO2013005168A2 (en) * 2011-07-05 2013-01-10 Lupin Limited Cannabinoid receptor modulators
SG11201402765TA (en) * 2011-12-30 2014-06-27 Hanmi Pharm Ind Co Ltd THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
CA2883386A1 (en) * 2012-09-14 2014-03-20 Eternity Bioscience Inc. Aminoisoquinoline derivatives as protein kinase inhibitors
BR122021012629B1 (pt) 2013-02-01 2022-06-07 Wellstat Therapeutics Corporation Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
EP3027590A1 (en) * 2013-07-31 2016-06-08 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
AU2014347027A1 (en) 2013-11-06 2016-06-23 Bristol-Myers Squibb Company GSK -3 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
JP6239149B2 (ja) 2014-04-25 2017-11-29 ファイザー・インク 複素芳香族化合物およびそのドーパミンd1リガンドとしての使用
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
WO2016120808A1 (en) * 2015-01-28 2016-08-04 Minoryx Therapeutics S.L. Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
EP1027050B1 (en) 1,3-thiazoles as adenosine a3 receptor antagonists for the treatment of allergy, asthma and diabetes
TWI567067B (zh) TrK抑制化合物
US20140079693A1 (en) Kinase inhibitors and methods of their use
IL271259B2 (en) Compounds and compositions for treating conditions associated with nlrp activity
EP4233834A2 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
MX2012004662A (es) Metodos de administracion de una terapia con pirfenidona.
JP2005510473A5 (cg-RX-API-DMAC10.html)
AR082458A1 (es) Combinacion que comprende un farmaco antipsicotico y un agonista de taar1
JP2016538313A5 (cg-RX-API-DMAC10.html)
HRP20180199T1 (hr) Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1)
JP2010513448A5 (cg-RX-API-DMAC10.html)
JP2005523901A5 (cg-RX-API-DMAC10.html)
WO2002051442A1 (en) Concomitant drugs
JP2019505595A5 (cg-RX-API-DMAC10.html)
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов
CA3120351A1 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
RU2012108423A (ru) Ацилгуанидиновые производные с азотсодержащим циклом
HUP0103893A2 (hu) Heterociklusos csoporttal szubsztituált propanolaminszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JP2023503465A5 (cg-RX-API-DMAC10.html)
JP2001114690A (ja) p38MAPキナーゼ阻害剤
JP2015500267A5 (cg-RX-API-DMAC10.html)
AU2016203591A1 (en) An iloperidone metabolite for use in the treatment of psychiatric disorders
PE20071086A1 (es) DERIVADOS DE PIRAZOLOISOQUINOLINA COMO INHIBIDORES DE LA CINASA p38
JP2008115166A5 (cg-RX-API-DMAC10.html)
CN107709325B (zh) 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途